gms | German Medical Science

77. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

24.05. - 28.05.2006, Mannheim

Tacrolimus – a new option in therapy-resistant chronic external otitis (EO)

Meeting Abstract

  • corresponding author presenting/speaker Philipp P. Caffier - Univ.-ENT Dept., Charité Campus Mitte, Berlin, Germany
  • Babak Mayelzadeh - Univ.-ENT Dept., Charité Campus Mitte, Berlin, Germany
  • Wolfgang Harth - Dermatology Dept., Vivantes Klinikum Prenzlauer Berg, Berlin, Germany
  • Benedikt Sedlmaier - Univ.-ENT Dept. Charité Campus Mitte, Berlin, Germany

German Society of Otorhinolaryngology, Head and Neck Surgery. 77th Annual Meeting of the German Society of Otorhinolaryngology, Head and Neck Surgery. Mannheim, 24.-28.05.2006. Düsseldorf, Köln: German Medical Science; 2006. Doc06hno030

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter:

Veröffentlicht: 7. September 2006

© 2006 Caffier et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.



Introduction: The OE is a nonspecific diffuse inflammation of bacterial, viral or mycotic origin. Eczematous integument changes of the acoustic meatus have an important role to play in the individual disposition. The standard therapy consists in the local application of corticosteroids, antibiotics or antimycotics. Recurrent exacerbation in chronic therapy-resistant OE represents a special challenge for the attending physician. Tacrolimus belongs to a new generation of locally applicable immune modulators, which are successfully used in dermatology for the treatment of inflammatory skin diseases.

Methods: In a prospective clinical study, the effectiveness of Tacrolimus ointment was examined in 40 patients with otherwise therapy-refractory uninfectious chronic OE. Every 2nd (-3rd) day, an ear wick containing Protopic® 0.1% was inserted into the external auditory canal, altogether, the wick was changed three times. Treatment efficiency was evaluated on the basis of re-examinations, a standardized findings sheet and photo-documentation.

Results: The preliminary results show a clear improvement in more than 80% of the cases (33 pat.). In many patients a complete healing of the clinical picture was to be seen. Within the observation period, no relevant local or systemic side effects were observed, except for a local feeling of heat, occasional skin burning (9 pat.) and itching (1 pat.).

Conclusions: The local short-term application of Tacrolimus into the external auditory canal has shown to be an effective and salubrious option in the treatment of chronic therapy-resistant OE. With the corticosteroid-free ointment, which selectively affects the immune system of the skin, even persistent cases with a long lasting course of disease can be treated with promising success.